Nadine E. Van Der Beek

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Muscle Regeneration Failure May Lead to Clinical Features of Myopathy in Anti-IgLON5 Disease.

Muscle Regeneration Failure May Lead to Clinical Features of Myopathy in Anti-IgLON5 Disease.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: July 13, 2026

Central nervous system histopathological findings in classic infantile Pompe disease: a systematic review with clinical relevance.

Central nervous system histopathological findings in classic infantile Pompe disease: a systematic review with clinical relevance.

Journal: Journal of neurology

Published: May 07, 2026

Quantitative Muscle MRI of the Lower Extremities Reveals Different Patterns of Involvement in Classic Infantile and Young Late-Onset Pompe Patients.

Quantitative Muscle MRI of the Lower Extremities Reveals Different Patterns of Involvement in Classic Infantile and Young Late-Onset Pompe Patients.

Journal: Journal of inherited metabolic disease

Published: March 01, 2026

Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations.

Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations.

Journal: European journal of neurology

Published: February 27, 2026

Correction: Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?

Correction: Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: December 15, 2025

Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?

Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: November 09, 2025

Unfavorable cardiovascular risk profile without increased event prevalence in late-onset Pompe disease: an individually matched cohort study.

Unfavorable cardiovascular risk profile without increased event prevalence in late-onset Pompe disease: an individually matched cohort study.

Journal: Orphanet journal of rare diseases

Published: September 22, 2025

Antibody formation and efficacy of enzyme replacement therapy in adults with Pompe disease: Unlocking long-term insights.

Antibody formation and efficacy of enzyme replacement therapy in adults with Pompe disease: Unlocking long-term insights.

Journal: Genetics in medicine : official journal of the American College of Medical Genetics

Published: August 15, 2025

Understanding the implementation of continuity-enhancing innovations as steps towards midwife-led continuity of care: A qualitative study using Normalization Process Theory.

Understanding the implementation of continuity-enhancing innovations as steps towards midwife-led continuity of care: A qualitative study using Normalization Process Theory.

Journal: PloS one

Published: August 07, 2025

Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.

Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.

Journal: Therapeutic advances in rare disease

Published: July 02, 2025

Enzyme replacement therapies in adults with Pompe disease: from trials to real-world data.

Enzyme replacement therapies in adults with Pompe disease: from trials to real-world data.

Journal: Current opinion in neurology

Published: June 05, 2025

Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe disease.

Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe disease.

Journal: Journal of neuromuscular diseases

Published: May 21, 2025

Showing 1-12 of 72

Last Updated: 09/26/2026